
|Articles|June 1, 2014
EU Steps Up Manufacturing Inspection Efforts
Author(s)Guest Blogger
One of EMA’s key objectives this year is improvements in dealing with the “causes and impact of shortages of human medicines caused by GMP non-compliance and quality defects”.
Advertisement
One of EMA’s key objectives this year is improvements in dealing with the “causes and impact of shortages of human medicines caused by GMP non-compliance and quality defects”. The European Directorate for the Quality of Medicines & Healthcare, which is responsible for the European Pharmacopoeia but also runs its own inspection operations, has been tightening and updating guidelines on the testing of products.
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
Legal Risk in a Rumored AstraZeneca-BMS Deal: Q&A with Ron Lanton
2
FDA Grants Accelerated Approval to Tudriqev in Combination with Nivoumab for Advanced Melanoma
3
Your Questions Answered: The Biggest Pharma Stories of the Week of August 3-7, 2026
4
Tarsus Pharmaceuticals to Acquire Alkeus Pharmaceuticals for $450 Million
5




